Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular ... investors something to cheer about after they watched the shares sink rapidly ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The gross proceeds to the Company from this offering are expected to be approximately $7.4 million, before ... Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon ...

Shares of Allurion Technologies (ALUR, Financials) surged 80.5% in after-hours trading on Thursday ... Allurion emphasized earlier studies demonstrating that their non-invasive gastric balloon and ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual ... in its July 2024 offering to $6.00 per share after obtaining shareholder approval.